Signal Capital Names Biotech. Expert Vice Chairman

Jul 31 2009 | 9:46am ET

Alternative investments firm Signal Capital Management has named a biotech expert as executive and academic vice chairman.

Roger van Hanwehr is CEO of energy technology development company Solus and co-founder of consulting firm Arcxeon. He also teaches biotechnology at Georgetown University in Washington, D.C.

Hanwehr, a polymath with expertise in such diverse fields as biological and radiological defense, renewable energy and nanotechnology, will evaluate investment opportunities in his new role at Signal.


In Depth

Steinbrugge: Will Hedge Funds Help or Hurt During the Next Market Correction?

Sep 7 2016 | 11:55pm ET

Most investors have become accustomed to quick rebounds when markets correct, but...

Lifestyle

Quattrex Sports AG Debuts Soccer-Focused UCITS Fund

Sep 9 2016 | 9:54pm ET

Innovative alternative investment company Quattrex Sports has unveiled a new UCITS...

Guest Contributor

Malik: The Ever-Changing Middle Market and The Entering Class of 2016

Sep 2 2016 | 5:01pm ET

Deal sourcing and origination is only going to get more competitive given current...